Prelude Capital Management’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Prelude Capital Management’s Portfolio LUMO Stock Details LUMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-78	Closed	-$20K	–	2221
2014 Q1	$20K	Buy	+78	New	+$23.8K	﹤0.01%	1690

Other funds holding LUMO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Prelude Capital Management's LUMO Position: Q2 2018 in Review

Prelude Capital Management sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q2 2018, closing a stake of 522 shares — an estimated $34K sold.

Prelude Capital Management first reported a position in LUMO in Q1 2015 and held it in 10 quarters. The position peaked at $304K in Q2 2015. 106 funds tracked by Wall St. Rank hold LUMO as of Q2 2018.

Prelude Capital Management reported no remaining Lumos Pharma, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
Prelude Capital Management sold 522 Lumos Pharma, Inc. Common Stock shares in Q2 2018, an estimated $34K.
Prelude Capital Management first reported a position in Lumos Pharma, Inc. Common Stock in Q1 2015 and held it in 10 quarters.
Prelude Capital Management's Lumos Pharma, Inc. Common Stock position peaked at $304K in Q2 2015.
106 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q2 2018.

Based on Prelude Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.